Biologics have revolutionized – and are revolutionizing – the treatment of many serious disorders. The evidence acquired from more than 10 years of clinical experience, with more than 50 biosimilar drugs and more than 700 million patient-days' exposure in Europe, shows that approved biosimilars can be used as safely and effectively as originator biologics. Yet concerns persist about biosimilars – particularly in curative cancer treatment, where they are relatively recent therapeutic options. 'Fast Facts: Biosimilars in Hematology and Oncology' provides a concise overview of emerging global practice in this fast-moving area together with practical information on adding biosimilars to a formulary and switching patients. Contents: ‧ Biologics and the need for biosimilars ‧ Why do we need biosimilars? ‧ How is the quality of biosimilar medicines assured? ‧ Legal issues ‧ Switching, interchangeability and extrapolation ‧ Safety and pharmacovigilant ‧ Global issues ‧ Formulary considerations: pharmacy issues ‧ Formulary considerations: supportive care biosimilars ‧ Formulary considerations: therapeutic anti-cancer biosimilars ‧ Communication and awareness